兰地洛尔预防肺癌术后复发:III期多中心随机对照试验方案
本研究为III期多中心随机对照试验,计划入组400例肺癌根治术后患者,比较单纯手术与围手术期使用超短效β1受体阻滞剂兰地洛尔3天对肿瘤复发的影响。主要终点为术后2年无复发生存率和总生存率。
要点
- 围手术期交感神经活性增高可能促进肿瘤转移,β受体阻滞剂或可延长癌症患者生存。
- 兰地洛尔是日本开发的超短效β1选择性阻滞剂,拟用于预防肺癌根治术后复发。
- 主要终点为术后2年无复发生存率和总生存率,计划入组400例。
核心结论
- 本试验旨在回答兰地洛尔能否降低肺癌根治性手术后的癌症复发。
研究设计与样本
- III期、多中心、随机、两平行组试验,比较单纯手术与手术联合围手术期兰地洛尔给药3天。
- 计划从12家日本机构入组400例肺癌患者。
主要发现
- 原文未报告研究结果,仅描述研究方案。
关键数值与推荐
- 主要终点为肺癌根治性手术后2年无复发生存率和总生存率。
- 次要终点包括癌症复发后的额外治疗、安全性事件和术后并发症发生率。
临床怎么用
- 若试验证实有效,围手术期使用兰地洛尔可能成为降低肺癌术后复发的干预策略。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed that use of beta blockers can be associated with the prolonged survival of patients with cancer. The objective of this study is to evaluate the preventive effects of landiolol hydrochloride, which is an ultra-short-acting beta-1-selective blocker that has been developed in Japan, on reducing recurrence of cancer after curative surgery for patients with lung cancer. METHODS: The present study is a phase III, multicenter, randomized trial with two parallel groups of patients with lung cancer, comparing surgery alone and surgery with landiolol administration for three days during the perioperative period. A total of 400 patients will be enrolled from 12 Japanese institutions. The primary endpoint is two-year relapse-free survival and overall survival after curative surgery for lung cancer. The secondary endpoints are additional treatment after recurrence of cancer, safety events, and the incidence of postoperative complications. DISCUSSION: The principal question addressed in this trial is whether landiolol can reduce recurrence of cancer after curative surgery for lung cancer. TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCT2011180004. Registered 17 January 2019.
引用
- Yamamoto H, Hamasaki T, Onda K, et al. Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients. Trials. 2019. PMID: 31829248. doi:10.1186/s13063-019-3904-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。